Home | About the eMC | Help | Mobile
eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
Advanced search
Get Medicines Compendium UK app here

Bayer plc
Bayer House, Strawberry Hill, Newbury, Berkshire, RG14 1JA
Telephone: +44 (0)1635 563 000
Fax: +44 (0)1635 563 393
WWW: http://www.bayer.co.uk

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?
Patient Information Leaflet last updated on the eMC: 26/09/2011
PIL Zevalin 1.6 mg/ml, Kit for radiopharmaceutical preparation for infusion

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 26/09/2011 and displayed until Current
Reasons for adding or updating:
  • Change to Further Information section
  • Change to date of revision
Updated on 09/08/2011 and displayed until 26/09/2011
Reasons for adding or updating:
  • Change to date of revision
  • Change to Marketing Authorisation Holder
  • Change to MA holder contact details
Updated on 13/10/2009 and displayed until 09/08/2011
Reasons for adding or updating:
  • Change/addition of instructions for reconstitution and/ or administration
  • Improved Electronic Presentation
  • Change to Further Information section
  • Change to date of revision
  • Change of contra-indications
  • Change to information about pregnancy or lactation
  • Extra statutory information
  • Changes to therapeutic indications
Updated on 16/06/2008 and displayed until 13/10/2009
Reasons for adding or updating:
  • Change to date of revision
  • Change to Further Information section
Updated on 23/05/2008 and displayed until 16/06/2008
Reasons for adding or updating:
  • Change to date of revision
  • Change to warnings or special precautions for use
  • Change to side-effects
  • Changes to therapeutic indications
Updated on 11/04/2008 and displayed until 23/05/2008
Reasons for adding or updating:
  • Transfer to upgraded management system
Updated on 07/03/2008 and displayed until 11/04/2008
Reasons for adding or updating:
  • Change to warnings or special precautions for use
  • Change to instructions about overdose
  • Change to side-effects
  • Change of active ingredient
  • Change to date of revision
  • Change of Distributor details
Updated on 13/06/2007 and displayed until 07/03/2008
Reasons for adding or updating:
  • Company name change or merger
Updated on 17/01/2007 and displayed until 13/06/2007
Reasons for adding or updating:
  • Change to side-effects
  • Change to storage instructions
  • Change to date of revision
  • Extra statutory information
  • Change to warnings or special precautions for use
Updated on 04/01/2006 and displayed until 17/01/2007
Reasons for adding or updating:
  • Change to warnings or special precautions for use
  • Change to side-effects
  • Change to date of revision
Updated on 02/11/2005 and displayed until 04/01/2006
Reasons for adding or updating:
  • Change to dosage and administration
  • Change to date of revision
  • Change to warnings or special precautions for use
  • Change to side-effects
Updated on 02/03/2004 and displayed until 02/11/2005
Reasons for adding or updating:
  • New PIL for new product

Active Ingredients/Generics

 
  ibritumomab tiuxetan